DMAC - DiaMedica Therapeutics Inc Stock Price, Fair Value and News

$9.39+0.05 (+0.54%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DMAC Price Action

Last 7 days

8.3%

Last 30 days

46.3%

Last 90 days

31.9%

Trailing 12 Months

72.2%

DMAC RSI Chart

DMAC Valuation

Market Cap

486.9M

Price/Earnings (Trailing)

-15.25

Price/Sales (Trailing)

1.6K

EV/EBITDA

-15.18

Price/Free Cashflow

-17.53

DMAC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DMAC Fundamentals

DMAC Revenue

Revenue (TTM)

205.0K

DMAC Earnings

Earnings (TTM)

-31.9M

Earnings Growth (Yr)

-37.39%

Earnings Growth (Qtr)

-11.96%

DMAC Profitability

EBT Margin

-15560.49%

Return on Equity

-61.87%

Return on Assets

-55.96%

Free Cashflow Yield

-5.7%

DMAC Investor Care

Shares Dilution (1Y)

21.79%

DMAC Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	797.0K	636.0K	398.0K	205.0K
2019	589.0K	678.0K	767.0K	856.0K
2018	0	0	0	500.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CEO	Mr. Dietrich John Pauls MBA
WEBSITE	diamedica.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	16

DiaMedica Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for DiaMedica Therapeutics Inc? What does DMAC stand for in stocks?

DMAC is the stock ticker symbol of DiaMedica Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DiaMedica Therapeutics Inc (DMAC)?

As of Thu Dec 11 2025, market cap of DiaMedica Therapeutics Inc is 486.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DMAC stock?

You can check DMAC's fair value in chart for subscribers.

Is DiaMedica Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether DMAC is over valued or under valued. Whether DiaMedica Therapeutics Inc is cheap or expensive depends on the assumptions which impact DiaMedica Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DMAC.

What is DiaMedica Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 11 2025, DMAC's PE ratio (Price to Earnings) is -15.25 and Price to Sales (PS) ratio is 1.6 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DMAC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on DiaMedica Therapeutics Inc's stock?

In the past 10 years, DiaMedica Therapeutics Inc has provided 0.179 (multiply by 100 for percentage) rate of return.